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Serotype-specific immunity to Streptococcus pneumoniae is conferred by antibodies to the capsular polysac-
charides, which define the 90 known serotypes. Whether antibody to the species-common cell wall polysaccha-
ride (C-Ps) is protective has been a matter of controversy. Here we show that C-Ps given intranasally with
mucosal adjuvant increased the resistance of mice to experimental nasopharyngeal colonization by capsulated
S. pneumoniae of serotype 6B. This immunity could be induced in mice congenitally lacking immunoglobulin
but was dependent upon CD4 T cells. Elimination of the charged amino group on the polymer backbone by
N acetylation of C-Ps reduced the immunity, as did treatment of the mice with antibody to the cytokine
interleukin-17A at the time of challenge, both consistent with the hypothesis of T-cell activation due to the
zwitterionic motif of the polymer. C-Ps also protected in a model of fatal aspiration pneumonia by heavily
capsulated serotype 3. These findings suggest a novel immunization strategy against S. pneumoniae.
Streptococcus pneumoniae (pneumococcus) can asymptom-
atically colonize the human nasopharynx, but it also causes
pneumonia and, particularly in infancy, other diseases ranging
from otitis media to fatal systemic infections. Pneumococcal
otitis is a major cause of morbidity and expense in industrial-
ized nations, and in the developing world almost one million
children yearly die of pneumococcal diseases (57). The capsu-
lar polysaccharides (PS), which define the 90 known serotypes,
impede the phagocytosis of pneumococci. Antibodies to the PS
are opsonic, confer serotype-specific protection, and have been
called the only significant mechanism of acquired immunity
(20). Current vaccines are based on injected mixtures of PS
chosen for prevalent serotypes: plain PS vaccine includes 23
serotypes and immunizes mature humans but generally is not
efficacious in infancy. Protein-conjugated PS vaccine protects
infants against seven serotypes prevalent in systemic infections
(4) but is costly to make and administer and subject to evasion
by the increasing prevalence of nonvaccine serotypes (24).
Simpler approaches with broader coverage are being sought.
Certain pneumococcal “species” antigens (common to all
serotypes) have been shown to have immunoprotective poten-
tial despite the PS encapsulation, e.g., the surface proteins
PspA, PspC, and PsaA and the cytolysin pneumolysin (6); the
recent use of genomics has identified several dozen additional
species proteins (56). Immunity has been induced by such
antigens in animal models, but no vaccine based on species
antigens has been licensed. Evidence was recently presented
that natural immunity to pneumococci increases with age in
early childhood without detectable antibodies to the PS, im-
plying the possibility that other antigens are involved (31).
Pneumococcal cell wall polysaccharide (C-Ps), a ribitol tei-
choic acid linked to the muramic residues of the cell wall
peptidoglycan (9), and the membrane-bound lipoteichoic acid
(LTA), consisting of the identical teichoic acid with a glyco-
lipid end group (13), are much-studied species antigens. Nat-
ural antibody to the phosphorylcholine (PCho) determinant of
pneumococcal teichoic acid was reported in 1981 to be protec-
tive in mice (8), and accordingly, the elicitation of antibodies
with protein-coupled C-Ps or PCho as a species vaccine has
been explored (29, 47, 48, 53). Protection was found in some
model systems; in others, however, C-Ps or PCho antibodies
were reported to be nonprotective (38, 39, 47), a result attrib-
uted to exclusion by the capsular PS (45). Similarly, antibodies
to the “F antigen” expressed in LTA were once thought pos-
sibly to confer species protection, but follow-up studies dis-
counted this view (1).
Most research on induction of pneumococcal immunity has
used mice challenged by the intraperitoneal or intravenous
route. Although the pathogenesis of pneumococcal systemic
infection has been analyzed in detail, the mechanism of naso-
pharyngeal (NP) carriage, which precedes much of natural
pneumococcal disease is less well understood (49, 50). Several
workers recently have investigated the role of virulence factors
in mucosal colonization (2, 3, 41, 42). Immunity to colonization
can be induced: PS conjugate vaccine reduces carriage in chil-
dren and induces herd immunity in adults (12, 30). Certain of
the species protein antigens have also been shown to induce
resistance to colonization in animal models (2, 7) and perhaps
also in humans (35). Investigation of “phase variation” by
Weiser and colleagues has revealed a mechanism whereby the
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subcapsular antigens of pneumococci, particularly PCho, may
be more accessible in colonization than in bacteremia (26, 54).
Pursuing an economical method to immunize with multiple
species antigens, we found that intranasal (i.n.) vaccination
with killed noncapsulated pneumococci (whole-cell vaccine
[WCV]) plus mucosal adjuvant protected rats against serotype
3 pneumonia and protected mice against NP colonization by
several other serotypes (32, 33). Unexpectedly, protection by
various WCV lots correlated with their C-Ps antigenic expres-
sion (unpublished), so in the present study we tried i.n. immu-
nization with purified C-Ps (given without coupling) plus mu-
cosal adjuvants. The responses of wild-type and mutant mouse
strains showed an antibody-independent CD4 T-cell-depen-
dent protective activity similar to that of the WCV (34) and
revealed an unexpected role of the cytokine interleukin-17A
(IL-17A). The results suggest both a mechanism of immunity
and an approach to immunization against pneumococci not
heretofore considered.
MATERIALS AND METHODS
Biologics. Purified pneumococcal cell wall polysaccharide was bought from the
Pneumococcal Reference Laboratory, Statens Seruminstitut (SSI), Copenhagen,
Denmark. The purification from strain CSR SCS2 and properties have been
described previously (25): the teichoic acid component has the repeating unit -6)--
D-Glcp-(1–3)--D-AATGalp-(1–4)--D-[6-PCho]GalNAc-(1–3)--D*GalNAc-(1–
1)-D-ribitol-5-P(O-. The asterisk indicates the position of a second phosphoryl-
choline side group in some strains (13, 25). The linkage of teichoic acid to the cell
wall muramic acid, which has not been defined, is difficult to break without
degrading the former (13), so C-Ps preparations, including that from SSI (25),
typically include fragments of peptidoglycan. The SSI preparations are free of F
antigen and contain about 1% “protein,” consisting mainly of oligopeptides of
the residual peptidoglycan rather than proteins per se (I. Skovsted, SSI, personal
communication); here, no F antigen was detectable by enzyme-linked immu-
nosorbent assays (ELISAs) (see below) in samples assayed at up to 1,000 g/ml,
and the 1% protein value was confirmed by using the Bradford assay kit (Bio-
Rad, Hercules, CA) and A280. Unless otherwise mentioned, the SSI preparations
were used as furnished and referred to as C-Ps. For one study, C-Ps was further
purified here by a 24-hour exposure at 4°C to 10% (wt/vol) trichloroacetic acid
followed by centrifugation and reisolation from the supernatant by ethanol-
acetone fractionation as previously described (9); recovery of C-Ps antigenicity as
assayed by ELISA inhibition with TEPC-15 antibody (see below) was 63%, while
the density of silver-stained bands in sodium dodecyl sulfate-polyacrylamide gels
(SDS-PAGs) (presumably peptides) was reduced by ca. 90% (see Fig. 2A). C-Ps
was periodate oxidized by 16 h of incubation at 25°C in a 0.28-ml aqueous
solution containing 5 mg of C-Ps and 3 mg of NaIO3. Five microliters of glycerol
was added to reduce any excess periodate. Glycerol, sodium iodate, and oxidized
C-Ps fragments of 3 kDa were removed by ultrafiltration with a Centricon
YM-3 device (Millipore Corp., Bedford, MA). Recovery of C-Ps antigenicity was
6% that of a control preparation made by first incubating the NaIO3 with
glycerol, then mixing with C-Ps, and ultrafiltration. C-Ps was N acetylated with
acetic anhydride in 5% (wt/vol) NaHCO3 and dialyzed as previously described
(52); in this procedure, which should not disrupt the polymer, C-Ps antigenicity
was 84% conserved.
Cholera toxin (CT) and cholera toxin B subunit (CTB) were from List Bio-
logical Laboratories (Campbell, CA), muramyl dipeptide (MDP), and the
TEPC-15 monoclonal antibody to the PCho determinant of C-Ps were from
Sigma (St. Louis, MO).
ELISA. Assays for murine antibodies to C-Ps were done in NUNC-Immuno
96-microwell plates (Nalge Nunc International, Rochester, NY) coated over-
night with C-Ps (5 g/ml). After antigen adsorption, the plates were washed with
phosphate-buffered saline containing 0.05% Tween (PBS-T) and blocked with
5% fetal bovine serum (FBS) in PBS-T. To distinguish PCho-specific antibodies
from C-Ps “backbone”-specific antibodies, the diluted antibody samples were
first coincubated with PBS-T alone or PBS-T with phosphorylcholine (100 g/ml;
Sigma) for 30 min at room temperature, after which samples were added to the
ELISA plates and incubated at room temperature for 2 h. Plates were washed
with PBS-T, and secondary antibody to mouse immunoglobulin G (IgG) or IgM
(Sigma) was added and incubated at room temperature for 1 hour. The plates
were washed and developed with SureBlue 3,3,5,5-tetramethylbenzidine micro-
well peroxidase substrate (KPL, Gaithersburg, MD). Anti-C-Ps antibody titers
were determined against a standard serum sample from a C-Ps-immunized
mouse whose value was arbitrarily set at 1,000 units/ml. Percent reduction by
phosphorylcholine was calculated to ascertain to what extent the measured
antibodies were directed against PCho. C-Ps antigenicity of various teichoic acid
preparations was assayed by inhibition of the ELISA in which mouse monoclonal
antibody to PCho (TEPC-15; Sigma) was premixed with serial dilutions of C-Ps
(as the standard) or the modified antigens before application to the C-Ps-coated
plates. Antibodies to whole pneumococci were assayed by coating the plates with
108 killed cells/ml before the blocking step as described previously (34). F-
antigen activity was assayed by ELISAs in which the wells were coated with
TEPC-15 (1 g/ml in PBS) to capture antigens expressing PCho. Blocking and
dilution of samples and secondary reagents were with PBS containing 5% FBS
(no Tween), and washing was with PBS alone. Samples were added and incu-
bated at room temperature for 2 h; after the wells were washed, they were
incubated with a 1:2,000 dilution of rabbit antiserum to group C Streptococcus
(SSI, Denmark), known to bind F antigen (46), then washed, and incubated with
horseradish peroxidase-conjugated antibody to rabbit IgG (Southern Biotech,
Birmingham, AL). Results were expressed as the concentration of sample gen-
erating a 0.2 increase in A450 compared to wells reacted without sample.
Immunization of mice. Mice were obtained from the Jackson Laboratory, Bar
Harbor, Maine, unless otherwise noted. The age of the mice at the time of the
first immunization was between 4 and 6 weeks. C57BL/6J mice were used as
wild-type animals. C57BL/6J muMT/ mice (B6.129S2-Igh-6tm1Cgn/J, in which
B-cell development is blocked at the pro-B stage [27]) are referred to as antibody
deficient. With age, some of these mice tend to develop low levels of IgM and
IgA antibodies; however, ELISAs of serum or salivary samples obtained follow-
ing immunization showed no detectable antibodies to noncapsulated pneumo-
cocci. T-cell-deficient mice, nu/, were compared to their respective nu/
littermates. Major histocompatibility complex (MHC) class II-deficient mice
(B6.129-H2-Ab1tm1Gru N12, with a disruption of the H2-Ab1 gene [16]) were
from Taconic Inc. (Germantown, NY); these mice lack CD4 T cells. Immuni-
zation i.n. with C-Ps or its derivatives was done by instilling 10 l of adjuvant
mixed with antigen; secondary immunizations were given after 1 week. Separate
study with methylene blue showed that, in unanesthetized mice, this volume of
immunizing solution does not reach the lung (data not shown).
Colonization model. To determine susceptibility to NP colonization, i.n. chal-
lenge with live encapsulated pneumococci was done as described previously (32)
4 to 5 weeks after the second immunization, with the one noted exception in
which challenge was done 5 months postimmunization. Briefly, serotype 6B
strain 0603 (32), containing predominantly the transparent phenotype (55) was
grown to mid-log phase in Todd-Hewitt broth with 0.5% yeast extract, harvested
by centrifugation, resuspended in saline at a concentration of 108 CFU/ml, stored
at 80°C, and thawed just prior to challenge. In unimmunized animals this
challenge results in CFU in the nasopharynx increasing through day 4 and
remaining about constant thereafter through at least day 14 postchallenge (33);
all the studies here determined colonization at day 6 or 7 postchallenge. The
mice were euthanized by CO2 inhalation. To determine NP colonization, an
upper respiratory culture was done by instilling sterile saline retrograde through
the transected trachea, collecting the first 6 drops (about 0.1 ml) from the
nostrils, and plating neat or diluted samples on blood agar plates containing 2.5
g gentamicin/ml; thus, 1 CFU/100 l of wash fluid or 10 CFU/ml was detect-
able. For calculations of geometric means, a sterile sample was assigned half the
lower limit of detection, or 5 CFU/ml.
Model of postcolonization inhalation pneumonia. The heavily capsulated se-
rotype 3 strain WU2, known to be highly virulent in mice (8), was used. The mice
were given 106 CFU in 10 l of saline i.n. to establish NP colonization; after 2
days, to mimic the aspiration of pneumococci, the mice were anesthetized with
isoflurane and given an additional dose of 106 CFU of WU2 in 100 l by the i.n.
route. In control animals, this challenge produced death within 4 or 5 days in
most and bacteremia in all.
Measurement of cytokine secretion by splenocytes. Cellular suspensions of
splenocytes were obtained by passing spleens from immunized mice through a
70-m cell strainer (BD Biosciences, Bedford, MA). The cells were washed, and
red blood cells were removed by hemolysis. The cells were plated into 24-well
tissue culture plates at a concentration of 105 cells/well in 500 l of Dulbecco
modified Eagle medium (BioWhittaker, Walkersville, MD) containing 10% low-
endotoxin defined FBS (HyClone, Logan, UT) and ciprofloxacin (10 g/ml, gift
from Miles Pharmaceuticals). Following 72 hours of stimulation with concanavalin A
(5 g/ml; Sigma), C-Ps (at 10 and 100 g/ml), or heat-killed pneumococcal strain
0603 (equivalent to 106 CFU/ml), supernatants were collected following centrif-
ugation and stored at 80°C until analyzed by ELISA for gamma interferon,
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IL-4, or IL-17A concentration (R&D Systems, Minneapolis, MN). Supernatants
were analyzed in duplicate and read against a standard, following directions
provided by the manufacturer.
Neutralization of IL-17A in vivo. Rabbit antibody to mouse IL-17A was ob-
tained as described previously (10). The IgG fraction was purified using the
Melon gel IgG purification kit (Pierce, Rockford, IL) according to the manufac-
turer’s instructions. Mice that had been previously immunized with C-Ps plus CT
were randomized to receive either an intraperitoneal injection of 1 ml of normal
rabbit serum (Sigma) or the same serum containing about 200 g of anti-mouse
IL-17A antibody. Serum was administered just prior to challenge with pneumo-
cocci and 3 days later. Mice were sacrificed on day 6 after challenge for deter-
mination of NP colonization.
Statistical analysis. Serum antibody and NP colonization density was compared
by Student’s t test for normally distributed data, the Mann-Whitney U test for
nonnormally distributed data, or by the Kruskal-Wallis test with Dunn’s correction
for multiple comparisons using PRISM (version 4.0a; GraphPad Software, Inc.).
Survival analysis by Kaplan-Meier analysis was performed using PRISM as well.
RESULTS
Intranasal C-Ps with adjuvant protects mice against pneu-
mococcal nasopharyngeal colonization. C-Ps (200 g per im-
munization) given i.n. twice at 1-week intervals as a droplet
without adjuvant was nonprotective against pneumococcal col-
onization (data not shown); therefore, mucosal adjuvants were
used. Because enterotoxin-type adjuvants like cholera toxin
can induce transient nonspecific protection in the NP (32), the
experiments below always compared antigen plus adjuvant ver-
sus adjuvant alone. Mice were immunized i.n. (sequentially,
twice) with 2, 20, or 200 g of C-Ps mixed with 1 g of CT as
adjuvant or with CT alone and challenged i.n. 4 weeks later
with serotype 6B (Fig. 1A). The mice receiving 200 g of C-Ps
plus CT had significantly lower colonization density than mice
that received the adjuvant alone (comparison of CFU recov-
ered from tracheal washes, P  0.004 by the Mann-Whitney
test). The immunity was tested here 4 weeks after the second
immunization; a separate study showed that immunity per-
sisted at least 5 months postimmunization (comparison of
CFU between mice immunized with C-Ps plus CT versus CT
alone, P 0.04 by the Mann-Whitney U test [data not shown]).
Four lots of the SSI C-Ps (D2, E2, E6, and G4) were tested,
and all induced immunity (data not shown). In general, the
CFU of adjuvant-only controls varied among experiments;
however, particularly when control CFU was high, immunity
was apparent in a significant reduction of CFU in the C-Ps-
vaccinated animals, although there may not have been a dif-
ference in the incidence of culture negativity (e.g., see Fig. 3C).
CTB, the nontoxic binding subunit of CT, also was an effective
adjuvant: with 4 g of CTB, C-Ps reduced NP colonization by
serotype 6B (P  0.049) (Fig. 1C).
Serum antibody responses. Mice receiving the immunizing
dose of 200 g C-Ps with CT had significantly higher serum
IgG anti-C-Ps antibody titers than the CT-only controls: the
FIG. 1. Effect of intranasal immunization with C-Ps upon pneumo-
coccal colonization in C57BL/6 mice. For panels A and C, each data point
represents the density of nasopharyngeal colonization in CFU/ml of tra-
cheal wash for each mouse, with sterile samples assigned a value of 5 (half
the lower limit of detection of 10). The horizontal bar shows the geometric
mean CFU/ml for each group. A. Immunization was with C-Ps in doses
indicated and with 1 g of cholera toxin where indicated. Three weeks
after secondary immunization, the mice (n  16 for each group) were
challenged intranasally with a strain of serotype 6B. Reduction of CFU
recovered from tracheal wash was significant for mice immunized with 200
g C-Ps plus CT versus CT alone (P  0.004 by the Kruskal-Wallis test
with Dunn’s correction). B. Serum antibody determination in mice (n 
6 for each group) that received CT or CPS (200 g) plus CT. IgG
serum antibodies to C-Ps were measured by ELISA; mice that received
CPS (200 g) plus CT had significantly more anti-C-Ps IgG 4 weeks
after the second intranasal immunization (P  0.002 by the Mann-
Whitney U test). C. Immunization was with 200 g of C-Ps plus 4 g
of cholera toxin B subunit or CTB alone. Mice (n 12 for each group)
were challenged with a strain of serotype 6B (comparison of density of
colonization between mice that received C-Ps plus CTB versus CTB
alone, P  0.049 by Student’s t test of log-transformed data).
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geometric mean was about sixfold greater in C-Ps-immunized
mice compared to controls (P 0.002 by the Mann-Whitney U
test; Fig. 1B). Anti-C-Ps IgG antibodies in both control and
C-Ps-immunized mice were predominantly directed against the
PCho component (median reduction by phosphorylcholine,
	90%).
Effect of further purification or modification of C-Ps. To
investigate possible contribution of coisolated proteins or pep-
tidoglycan, the SSI C-Ps was further purified with 10% (wt/vol)
trichloroacetic acid (TCA) at 4°C, which can precipitate pro-
teins and also slowly detach the peptidoglycan from the tei-
choic acid (9, 13). In SDS-PAGs with silver staining, C-Ps
displayed ca.12 bands; the TCA-purified derivative exhibited a
great reduction in the intensity of these bands (Fig. 2A), but
TCA-treated C-Ps reduced colonization from a serotype 6B
challenge as well as the untreated C-Ps did (Fig. 2B). To
further explore whether residual peptidoglycan fragments in
C-Ps could account for its activity in our model, MDP, a pep-
tidoglycan derivative known to be immunologically potent (58)
was tested directly; however, 20-g doses of MDP (with CT)
were nonprotective against pneumococcal colonization (data
not shown). The vicinal hydroxyls of the glucose and ribitol
residues make the teichoic acid subject to fragmentation by
periodate oxidation, while peptidoglycan is not. C-Ps was
oxidized with periodate and cleared of fragments by ultra-
filtration: the oxidized C-Ps did not reduce pneumococcal
colonization in a test in which the control C-Ps was protec-
tive (Fig. 2C).
Protection against pneumococcal colonization by C-Ps is
antibody independent and CD4-T-cell dependent. C-Ps was
tested to determine whether, like a whole-cell vaccine given
i.n., its protective effect against colonization could be antibody
independent and CD4-T-cell dependent (34). In muMT/
(immunoglobulin-deficient) mice, C-Ps was as effective as in
wild-type mice (Fig. 3A). In nu/ (T-cell-deficient) mice,
C-Ps was ineffective (P 	 0.05 versus CT alone), but it was
effective in nu/ controls (Fig. 3B). In MHC class II-deficient
mice, C-Ps did not confer any protection (Fig. 3C). Thus, like
WCV, C-Ps given i.n. with adjuvant elicited an antibody-inde-
pendent, CD4 T-cell-dependent protection against coloniza-
tion by capsulated pneumococci.
Role of the zwitterionic motif of C-Ps. The observation of
T-cell dependence suggested that the protection by C-Ps might
include a mechanism previously described in a different con-
text, whereby injection of C-Ps or other zwitterionic polysac-
charides (containing positive and negative charges within the
polymer backbone) into rats can induce abscess formation by
stimulating CD4 T cells (11, 52). The primary amino group
on each AATGal residue of C-Ps is positively charged, and N
acetylation to convert the amino to N acetyl groups (un-
charged) inhibited abscess formation (52). Accordingly, C-Ps
was N acetylated by the identical method. Figure 4 shows that
acetylated C-Ps, although retaining 84% of original TEPC-15
ELISA antigenicity, did not significantly reduce colonization
(P 	 0.05) in an experiment where untreated C-Ps was effec-
tive as expected (P  0.01 versus CT alone).
IL-17A mediates C-Ps-induced immunity to colonization.
An additional feature of the zwitterionic induction of abscess
formation is the participation of IL-17A (10). The pertinence
to the present work was evaluated in two ways. First, the ability
FIG. 2. Effect of further treatment of C-Ps with trichloroacetic acid or
periodate. A. Silver-stained SDS-PAG of 100-g samples of C-Ps (Statens
Seruminstitut) before (lane 1) and after (lane 2) extraction with TCA for
1 day at 4°C as described in Materials and Methods. B and C. Effect of
immunization with TCA-treated C-Ps plus CT (B) or periodate-oxidized
C-Ps plus CT (C) upon nasopharyngeal colonization of C57BL/6 mice by
serotype 6B. Mice were immunized intranasally with 1 g of CT and 200
g of C-Ps with and without prior treatment as indicated. The horizontal
bar shows the geometric mean CFU/ml for each group. Protection by
immunization with TCA-treated C-Ps plus CT was significant versus that
achieved by CT alone (P  0.0007 by the Mann-Whitney U test) and
similar to that with C-Ps plus CT (P  0.74). Oxidation of C-Ps with
periodate reduced protection (P  0.21 versus immunization with CT
alone by the Mann-Whitney U test), whereas the control preparation of
C-Ps incubated with glycerol-pretreated periodate was significantly effec-
tive (P 0.01 versus CT alone by the Mann-Whitney U test) (n 8 to 10
mice per group).
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of splenocytes from mice immunized with C-Ps plus CT versus
CT to secrete IL-17A in response to stimulation with C-Ps or
killed pneumococci was compared. As shown in Fig. 5A, IL-
17A secretion in response to stimulation with these pneumo-
coccal antigens was observed in splenocytes only from mice
that had been immunized with C-Ps plus CT, whereas the
response to a nonspecific stimulus, such as concanavalin A, was
similar in both groups. There was no detectable production of
gamma interferon or IL-4 in response to stimulation with C-Ps
or killed pneumococci (data not shown). Second, to test
whether IL-17A is a critical effector cytokine for immunity in
this model, mice immunized with C-Ps plus CT were treated
with antiserum to IL-17A just before challenge, and immunity
to pneumococcal colonization was reduced in comparison to
treatment with a control serum (Fig. 5B).
Intranasal immunization with C-Ps protects against fatal
pneumonia. Mice were inoculated i.n. with 106 CFU of sero-
type 3 strain WU2 in saline and 2 days later were given an
additional 106 CFU under isoflurane anesthesia. In pilot stud-
ies this inoculum resulted in 80% mortality within 7 days, with
the remainder of mice all showing signs of illness and/or bac-
teremia (data not shown). Mice were immunized with C-Ps
plus CT or CT alone, then challenged as described above, and
observed for 7 days; blood cultures were obtained on all sur-
vivors on day 7. As shown in Fig. 6, C-Ps plus CT significantly
protected against death (survival in mice that received C-Ps
plus CT versus CT alone, 60% versus 22%, respectively, P 
0.046 by Kaplan-Meier analysis). In addition, all the surviving
mice in the CT control group had bacteremia, whereas survi-
vors in the group treated with C-Ps plus CT did not.
DISCUSSION
After the 1981 report that PCho antibody in mice could be
protective against pneumococcal challenge (8), a number of
workers investigated this lead to develop a species immunogen.
Since C-Ps by itself is a poor systemic immunogen (29), protein
conjugates of PCho or C-Ps were used (29, 47, 53). Evidence of
FIG. 3. Effect of intranasal immunization with C-Ps upon pneumo-
coccal serotype 6B nasopharyngeal colonization in immunodeficient mice.
Mice were immunized with 1 g of CT and 200 g of C-Ps or CT alone
as indicated. The P values are calculated by the Mann-Whitney U test for
protection versus CT alone. A. muMT/ mice, deficient in immunoglob-
ulin were significantly protected compared with CT controls (P 0.01; 16
mice per group). B. Nude mice (nu/) were not protected (P 	 0.05) in
contrast to their heterozygote controls (nu/) (P  0.01; 10 mice per
group). C. Mice with a disruption of the MHC class II H2-Ab1 gene were
not protected (P	 0.1; 12 mice per group). The horizontal bar shows the
geometric mean CFU/ml for each group.
FIG. 4. Effect of N acetylation of C-Ps upon immunity to NP col-
onization. C-Ps was acetylated to convert the free amino to N acetyl
groups (52). C57B/6 mice were immunized with 1 g of CT and 200 g
of C-Ps or N-acetylated C-Ps as indicated. The density of colonization
in the tracheal wash of individual mice is shown. The horizontal bar
shows the geometric mean CFU/ml for each group. N-acetylated C-Ps
plus CT was not effective in reducing colonization (P 	 0.05 versus CT
alone by the Kruskal-Wallis test with Dunn’s correction), whereas
untreated C-Ps plus CT was effective (P  0.01) (n  6 to 10 mice per
group).
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protection was found in some studies (for example, references
48 and 53). In others, however, antisera raised by such conju-
gates (47) or monoclonal antibodies to PCho or backbone
determinants (39) appeared nonprotective, and an ultrastruc-
tural study concluded that pneumococci with “intact capsules”
would exclude C-Ps antibody (45). In humans, naturally ac-
quired C-Ps serum IgG antibody appeared uncorrelated with
immunity (38). However, interest in C-Ps as a protective anti-
gen, particularly with respect to colonization, was increased by
the description of pneumococcal phase variation (26, 55).
Compared to the “opaque” phenotype (predominant in the
bloodstream), the “transparent” phenotype (predominant in
the nasopharynx) expresses less capsular PS and more C-Ps;
thus, the PCho determinant may facilitate colonization by
binding to the platelet-activating factor receptor on human
mucosa. The transparent phenotype is susceptible to passively
administered human PCho antibody (14) and to the acute-
phase reactant C-reactive protein (15), which could have pro-
tective roles against pneumococci in the nasopharynx.
The present study has revealed what appears to be an addi-
tional C-Ps-induced host defense mechanism, one that can be
elicited by i.n. vaccination with uncoupled C-Ps. In the wild-
type mice, PCho-specific serum IgG antibody titers were in-
creased, which may have contributed to the protection ob-
served; however, these were unnecessary for protection in the
NP colonization model, as indicated by the protection in the
muMT/ animals. The immunity resembles that which we
described for a killed noncapsulated cell vaccine, WCV, in the
requirement for adjuvant, antibody independence, and CD4
T-cell dependence (32–34). The antibody independence also
resembles recent observations that clearance of pneumococci
from the nasopharynx of naı¨ve mice can occur without anti-
body (36) and that systemic clearance likely involves CD4 T
cells (21), but whether the underlying mechanisms, including
the critical role of IL-17A, are identical is presently uncertain.
To explore the protective potential of C-Ps in case pneumo-
cocci evaded NP clearance and invaded the lung, we sought a
model to reproduce the natural pathogenesis in which, some-
time after carriage is established, some insult, such as viral
infection or aspiration, overcomes nonspecific barriers to lower-
tract access. Thus, two days after an initial inoculation, an
additional bolus of bacteria was given with anesthesia, which
gave a consistently high fatality rate against which the effect of
vaccination could be determined. C-Ps protected significantly
in the model, indicating a potential for preventing invasion of
the lung. The result superficially resembles the study of Trolle
et al. in which a PCho-protein conjugate administered i.n.
induced both mucosal and serum antibodies to PCho and pro-
tected against lung infection of anesthetized mice challenged
FIG. 5. Secretion of IL-17A following immunization with C-Ps and
role in immunity to NP colonization. A) Cultured splenocytes from
mice immunized with C-Ps plus CT or CT alone were stimulated with
the agents indicated for 72 h, after which IL-17A production was
measured by ELISA. Increased IL-17A production due to C-Ps or
killed pneumococci was noted in splenocytes from mice immunized
with C-Ps plus CT. Shown is a representative experiment of at least
three experiments, which gave similar results. dmem, Dulbecco mod-
ified Eagle medium; conA, concanavalin A. B) Mice immunized with
C-Ps plus CT 4 weeks earlier received intraperitoneal injections of
rabbit serum with or without anti-mouse rabbit IL-17A antibody at the
time of pneumococcal i.n. challenge and 3 days later. Mice were sac-
rificed on day 6, and nasal washes were collected for quantification of
pneumococcal colonization. The horizontal bar shows the geometric
mean CFU/ml for each group. Immunized mice that received IL-17A
antibody had no reduction in the density of NP colonization (nonsig-
nificant versus CT alone), whereas immunized mice that received only
rabbit serum had significantly fewer recovered pneumococci from tra-
cheal washes (P  0.01 versus mice that received CT alone) (n  8 to
10 mice per group).
FIG. 6. Effect of intranasal immunization with C-Ps upon invasive
disease in C57BL/6 mice. Mice immunized with C-Ps plus CT or CT
alone were challenged by intranasal aspiration of type 3 strain WU2,
and survival was assessed twice daily. Mice immunized with C-Ps plus
CT survived significantly longer than mice that received CT alone (P
0.046 by Kaplan-Meier analysis) (n  9 or 10 mice per group).
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i.n. with serotype 3 (48); however, the extent of mechanistic
overlap is unknown. Although the PCho dosages in the two
studies were similar (15 g coupled to 500 g of carrier protein
compared to 200 g of C-Ps containing a maximum of 26 g of
PCho, assuming 100% purity), the conjugate was given in 50-l
volumes to anesthetized mice and reached the lung (known to
increase the systemic antibody response [18]), while we gave
(the nonconjugated) polysaccharide to nonanesthetized mice
in small volumes shown not to reach the lung. It remains to be
determined whether C-Ps will induce lung protection in
muMT/ mice, i.e., could be antibody independent, as is the
immunity to NP colonization.
The immunizing dosage of C-Ps is high in relation to immu-
nizing dosages of purified polysaccharides given systemically.
The i.n. administration by droplet, however, does not maximize
exposure of the immunogen to the nasal mucosa; unknown
proportions are quickly swallowed by the animals. Also, as
noted above, the mouse-immunizing dose of PCho-protein
conjugate used i.n. by Trolle et al. was similarly high (48). In
humans, the i.n. immunizing dosage of a meningococcal outer
membrane antigen was about 10-fold the systemic dosage (40).
Nonetheless, we have attempted to rule out components other
than the teichoic acid of the SSI C-Ps preparations that could
be responsible for the immunity observed. Residual capsular
PS is unlikely to contribute, because strain CSR SCS 2 was
derived from a heterologous capsular type (serotype 2) (5).
The SSI purification of C-Ps includes deproteinization with
chloroform-butanol and trypsin treatment (25); this and our
finding that activity remained after TCA repurification reduces
the likelihood that protection is attributable to coisolated
pneumococcal proteins. TCA also has the potential to detach
peptidoglycan from the teichoic acid (9, 13), and it seems likely
that the silver-staining PAG bands diminished by the TCA
procedure (Fig. 2A) represent residual peptidoglycan oli-
gopeptides known to be present in SSI C-Ps preparations.
Another approach to the peptidoglycan question was testing
muramyl dipeptide directly, which was nonprotective against
pneumococcal colonization. Finally, peptidoglycan, lacking
vicinal hydroxyls, is periodate resistant. Thus, the observed
reduction of immunity by periodate (Fig. 2C) indicates that
residual peptidoglycan is not solely responsible and that the
teichoic acid component of the C-Ps preparations is in-
volved. Although the SSI C-Ps lacks detectable F antigen,
not all molecules in pneumococcal lipoteichoic acid prepa-
rations equally express F activity (13). Thus, it is possible
that the C-Ps contained some coisolated LTA, a known
Toll-like receptor 2 agonist (17, 44), that contributed to the
protection we observed.
The immunologic response to polysaccharides in general has
been considered T-cell independent and characterized by a
primary humoral response of IgM production, rare IgG class
switching, and no immunologic memory (20). In contrast,
adaptive major histocompatibility complex class II-restricted
CD4 T-cell activation had been considered to be limited to
proteins or protein-polysaccharide-conjugated antigens. These
antigens are presented to T cells by MHC class II, leading to an
immune response characterized by the production of Th1 or
Th2 cytokines as well as IgG and the induction of immunologic
memory. However, beginning with capsules of Bacteroides
fragilis, Kasper and colleagues showed that polysaccharides
with a zwitterionic charge motif within the repeating unit could
activate CD4  T cells to form abscesses in a process re-
stricted by MHC class II. They found that such polymers are
oxidized by nitric oxide and presented by MHC class II by B
cells to T cells via interactions with  T-cell receptors (11, 51)
and that IL-17A is an effector of abscess formation (10).
Among the examples of polymers with such abscess induction
activity is pneumococcal C-Ps, and N acetylation of the poly-
saccharide abrogated the activity (52). Our present observa-
tions that immunity to pneumococcal colonization is inducible
by C-Ps in uncoupled form, that immunity is antibody inde-
pendent and MHC class II T cell dependent, and that immu-
nity is IL17A mediated all suggested that the activity (like
abscess induction) could be due to the zwitterionic motif of the
polymer. Consistent with this hypothesis, N acetylation of the
polysaccharide, which removes a positive charge in the poly-
mer backbone, resulted in an ineffective immunogen (Fig. 4).
The precise mechanism whereby IL-17A mediates protection
remains to be determined. There is abundant evidence from
mouse models that the IL-17 cytokine family plays a critical
role in neutrophil recruitment and abscess formation (10, 37,
59, 60) as well as induction of antimicrobial peptides (22, 23).
Both of these mechanisms may be responsible for the protec-
tion observed and are currently under investigation.
This hypothesis aside, it is noteworthy that the SSI C-Ps, if
presented mucosally with suitable adjuvant, induced immunity
to NP colonization against a serotype 6 strain and protection
against sepsis by serotype 3. The immunity to colonization
required CD4 T cells and the activity of IL-17A. This cyto-
kine, although much studied in the context of inflammation
(19, 28, 43), to our knowledge has not been viewed as an
effector of vaccine-induced bacterial immunity. Conceivably,
once primed for enhanced production in the nasopharynx, its
release could be triggered by a variety of potential pathogens
presenting the same signal as pneumococci. Studies are under
way to define the structural basis of activity of the C-Ps prep-
arations, to further characterize the effector mechanisms, and
to extend the observations to additional pneumococcal isolates
and related respiratory pathogens. In general, our findings and
recent reports from other laboratories (21, 36) commend at-
tention to antibody-independent, T-cell-mediated mechanisms
of immunity to pneumococci.
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